Alkermes plc - Ordinary Shares (ALKS) stock analysis

ALKS · Alkermes plc - Ordinary Shares

Latest recorded price: USD 46.53

Model-estimated fair value: USD 30.52. This assumption-based estimate is for general research and is not investment advice.

Sector and industry: Healthcare · Drug Manufacturers - Specialty & Generic

At $46.53, ALKS trades 52.4% above the model's base-case value of $30.52. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $21.79 in the conservative case and $41.07 in the optimistic case, with a valuation confidence score of 45/100. Fiscal 2025 figures: revenue growth 9.9%, free cash flow margin 32.5%, ROIC 7.8%. The model flags 1 risk signal for this company (1 high severity).

Similar companies in Healthcare